Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

110.23 +5.42 (+5.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 519,851
Open 105.98
Bid (Size) 105.50 (1)
Ask (Size) 114.05 (1)
Prev. Close 104.81
Today's Range 103.28 - 110.39
52wk Range 61.58 - 178.71
Shares Outstanding 56,937,682
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know
  Oppenheimer has decided to maintain its Outperform rating of Ascendis Pharma (NASDAQ:ASND) and lower its price target from $154.00 to $144.00. Shares of Ascendis Pharma are trading up 8.7% over the... 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-18.80%
-18.80%
1 Month
+24.46%
+24.46%
3 Month
+32.62%
+32.62%
6 Month
-10.27%
-10.27%
1 Year
-8.55%
-8.55%

More News

Read More
What 14 Analyst Ratings Have To Say About Ascendis Pharma
Via Benzinga
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge
Via Investor's Business Daily
Where Ascendis Pharma Stands With Analysts
Via Benzinga
Where Ascendis Pharma Stands With Analysts
Via Benzinga
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Via Benzinga
BofA Upgrades Ascendis Pharma After Promising TCP Phase 3 Data
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints
Via Benzinga
7 Biotech Stocks With Key Catalysts in March
Via InvestorPlace
Expert Ratings For Ascendis Pharma
Via Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
Via Benzinga
Pfizer Dives After FDA Rejects Its OPKO-Partnered Rare Disease Treatment
Via Investor's Business Daily
Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval
Via Benzinga
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
Via Benzinga
Earnings Scheduled For March 2, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Via Benzinga
Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.